Patents by Inventor James Shanahan

James Shanahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230404963
    Abstract: The present disclosure is directed to combinations of MetAP2 inhibitors and CDK4/6 inhibitors for the treatment and prevention of cancer.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 21, 2023
    Inventors: Peter CORNELIUS, James SHANAHAN, Bradley J. CARVER
  • BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF
    Publication number: 20230225996
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, metabolic dysfunction associated with a treatment in a subject having cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of, cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent.
    Type: Application
    Filed: March 9, 2023
    Publication date: July 20, 2023
    Inventors: Peter CORNELIUS, James SHANAHAN
  • Biomarkers of METAP2 inhibitors and applications thereof
    Patent number: 11612577
    Abstract: The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: March 28, 2023
    Assignee: SynDevRx, Inc.
    Inventors: Peter Cornelius, James Shanahan
  • METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
    Publication number: 20230048989
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Application
    Filed: February 28, 2022
    Publication date: February 16, 2023
    Inventors: John S. PETERSEN, James SHANAHAN
  • TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION
    Publication number: 20220280470
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 8, 2022
    Inventors: James SHANAHAN, Peter CORNELIUS
  • MetAP2 inhibitors and methods of treating obesity
    Patent number: 11304944
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: April 19, 2022
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Treatment for tumors driven by metabolic dysfunction
    Patent number: 11273142
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: March 15, 2022
    Assignee: SynDevRx, Inc.
    Inventors: James Shanahan, Peter Cornelius
  • TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION
    Publication number: 20210077452
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
    Type: Application
    Filed: May 7, 2020
    Publication date: March 18, 2021
    Inventors: James SHANAHAN, Peter CORNELIUS
  • METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
    Publication number: 20200155545
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Application
    Filed: January 27, 2020
    Publication date: May 21, 2020
    Inventors: John S. PETERSEN, James SHANAHAN
  • Treatment for tumors driven by metabolic dysfunction
    Patent number: 10646463
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 12, 2020
    Assignee: SynDevRx, Inc.
    Inventors: James Shanahan, Peter Cornelius
  • BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF
    Publication number: 20200129457
    Abstract: The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Peter CORNELIUS, James SHANAHAN
  • METAP2 inhibitors and methods of treating obesity
    Patent number: 10588904
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 17, 2020
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
    Publication number: 20180271856
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 27, 2018
    Inventors: John S. Petersen, James Shanahan
  • METAP2 inhibitors and methods of treating obesity
    Patent number: 10010544
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: July 3, 2018
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Multi-directional underwater lighting
    Patent number: 9845947
    Abstract: Apparatus and method provide underwater lighting to illuminate a site within a body of water in which underwater lighting apparatus is immersed during a lighting cycle. A housing is constructed of a heat-conductive material and LED arrays are affixed to the housing, within a sealed chamber, to conduct heat from the LED arrays to the housing such that heat generated by the LED arrays during the lighting cycle will be conducted directly to the housing and dissipated by the housing to the surrounding body of water. Light provided by the LED arrays is passed through corresponding lens members located for directing light in different directions. At the same time, fouling by marine organisms is resisted.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: December 19, 2017
    Inventor: Richard James Shanahan, III
  • METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
    Publication number: 20170326135
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 16, 2017
    Inventors: John S. Petersen, James Shanahan
  • MetAP2 inhibitors and methods of treating obesity
    Patent number: 9757373
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 12, 2017
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • METAP2 inhibitors and methods of treating obesity
    Patent number: 9750737
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 5, 2017
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION
    Publication number: 20170196830
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
    Type: Application
    Filed: January 11, 2017
    Publication date: July 13, 2017
    Inventors: James Shanahan, Peter Cornelius
  • METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
    Publication number: 20170028014
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Application
    Filed: August 2, 2016
    Publication date: February 2, 2017
    Inventors: John S. Petersen, James Shanahan